An FDA committee votes to roll out a new COVID vaccination strategy
(By Scott Hensley for NPR) A committee of advisers to the Food and Drug Administration voted unanimously on a proposal
Read moreCOVID-19
Moderna’s RSV shot 83.7% effective, late-stage trial shows
By Paige Twentier for Becker’s Hospital Review on January 18, 2023 Moderna’s respiratory syncytial virus vaccine candidate for older adults
Read moreWhat Older Americans Need to Know About Taking Paxlovid
By Judith Graham on January 18, 2023 for Kaiser Health News A new coronavirus variant is circulating, the most transmissible
Read moreXB what? BQ huh? Do you need to keep up with Omicron’s ever-expanding offspring?
(By Helen Branswell for STAT) It’s like clockwork now. Every few months, we’re warned that the Omicron variant of the
Read moreXBB.1.5’s transmissibility, severity: 4 Qs answered
(By Erica Carbajal for Becker’s Hospital Review) Health officials are keeping a close eye on omicron subvariant XBB.1.5 due to
Read moreIt’s not too late to get a COVID booster — especially for older adults
By Selena Simmons-Duffin for NPR on December 28, 2022 The U.S. has come a long way from two years ago
Read moreThree years on, the pandemic — and our response — have been jolting. Here’s what even the experts didn’t see coming
By Helen Branswell for Stat News on December 27, 2022 People who study infectious diseases and who work in public
Read moreAmerican life expectancy is now at its lowest in nearly two decades
By Yuki Noguchi for NPR on December 22, 2022 The average life expectancy for Americans shortened by over seven months
Read moreEntering the Winter Season, How Many Nursing Facility Residents and Staff Were Up-To-Date With Their COVID-19 Vaccines?
(By Priya Chidambaram and Alice Burns for The Kaiser Family Foundation Published: Dec 12, 2022) Moving into the holiday—and COVID-19/flu
Read moreAdults who took Paxlovid 50% less likely to be hospitalized with COVID-19: 10 CDC findings
(By Nika Schoonover for Becker’s Hospital Review) Adults who were prescribed Paxlovid for mild to moderate COVID-19 were 50 percent
Read more